"Is this normal market action for a biotech company so close to the finish line?  Nervous investors get out just before the real action begins?  As an example, Amarin hit its lows for 2018 on July 31...a scant 8 weeks before it went ballistic."  

Before hitting the Sept 24, 2018 milestone of announcing topline data that propelled them into "ballistic" territory, Amarin made April 2018 announcement on hitting target #events (end of dosing/start of patient follow ups) and June 2018 announcement on last patient study visit having occurred. Resverlogix/BETonMACE has yet to reach 250 events and start follow up.

April 2018: Amarin announced that REDUCE-IT is estimated to have reached the onset of the targeted 1,612 MACE events, anticipates that MACE from the study will be adjudicated through Q2 2018, and on track for reporting top-line results before the end of Q3 2018.

June 2018: Amarin announced  that the last patient study visit had occurred and reiterated that it anticipates having top-line results before the end of Q3 2018.